| First Posted | New Trial Filing | Phase | Status |
|---|---|---|---|
| 2026-06-02 | NCT07619339 A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer | Phase 1 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT06106802 | Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who… | Non-Small Cell Lung Cancer Metastatic | Recruiting |
| NCT06031688 | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14… | Recurrent Lung Non-Small Cell Carcinoma | Recruiting |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC… | Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT02864992 | Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06083857 | PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT07619339 | A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | Recruiting |
| NCT05782361 | POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC | Advanced Cancer | Active, Not Recruiting |